---
title: "石藥集團新藥 SYH2066 獲准開展臨牀試驗"
description: "石藥集團公佈，集團主研發的化學 1 類新藥 SYH2066 片獲中國國家藥品監督管理局批准，可在中國開展臨牀試驗。本次獲批的適應症為用於治療由呼吸道合胞病毒引起的呼吸道感染。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/257245297.md"
published_at: "2025-09-14T09:49:51.000Z"
---

# 石藥集團新藥 SYH2066 獲准開展臨牀試驗

> 石藥集團公佈，集團主研發的化學 1 類新藥 SYH2066 片獲中國國家藥品監督管理局批准，可在中國開展臨牀試驗。本次獲批的適應症為用於治療由呼吸道合胞病毒引起的呼吸道感染。

石藥集團 (01093.HK) 公佈，集團主研發的化學 1 類新藥 SYH2066 片獲中國國家藥品監督管理局批准，可在中國開展臨牀試驗。本次獲批的適應症為用於治療由呼吸道合胞病毒引起的呼吸道感染。

### Related Stocks

- [01093.HK - 石藥集團](https://longbridge.com/zh-HK/quote/01093.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | [Link](https://longbridge.com/zh-HK/news/276056763.md) |
| CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | CSPC Pharmaceutical Receives Regulatory Nods to Begin Drug Trials | [Link](https://longbridge.com/zh-HK/news/276035104.md) |
| Will China Literature Turn The Page? | China Literature Ltd. expects a net loss of up to 850 million yuan for last year, primarily due to a 1.8 billion yuan go | [Link](https://longbridge.com/zh-HK/news/276113491.md) |
| Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | Shenhua Energy Gets Securities Regulator's Nod for Share Placement Plan | [Link](https://longbridge.com/zh-HK/news/275851575.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/zh-HK/news/276051793.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。